OAM
RNAM

Oxford Asset Management’s Avidity Biosciences RNAM Stock Holding History

Oxford Asset Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,581
Closed -$461K – 711
2025
Q3 		$461K Buy
+10,581
New +$428K 0.15% 231
2024
Q4 		– Sell
-5,913
Closed -$272K – 578
2024
Q3 		$272K Buy
+5,913
New +$257K 0.23% 180

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oxford Asset Management's RNAM Position: Q4 2025 in Review

Oxford Asset Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 10,581 shares — an estimated $461K sold.

Oxford Asset Management first reported a position in RNAM in Q3 2024 and held it in 2 quarters. The position peaked at $461K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Oxford Asset Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Oxford Asset Management sold 10,581 Avidity Biosciences shares in Q4 2025, an estimated $461K.
  • Oxford Asset Management first reported a position in Avidity Biosciences in Q3 2024 and held it in 2 quarters.
  • Oxford Asset Management's Avidity Biosciences position peaked at $461K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Oxford Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.